Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone

A preliminary study

Travis M. Scott, Monica Rivera Mindt, Chinazo O. Cunningham, Franchesca Arias, Kelly Coulehan, Aprille Mangalonzo, Pat Olsen, Julia H. Arnsten

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. Methods: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age=45.2years [SD=8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence. Results: Depressive symptomatology was not significantly related to neuropsychological change (p's>.05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r's=.52-60; p's<.05). Conclusions: Among OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD. Trial registration:NCT01108679. Registered 21 April 2010.

Original languageEnglish (US)
Article number48
JournalSubstance Abuse: Treatment, Prevention, and Policy
Volume12
Issue number1
DOIs
StatePublished - Nov 15 2017

Fingerprint

Opiate Alkaloids
Opioid Analgesics
Learning
Medication Adherence
Neuropsychological Tests
Patient Compliance
Naloxone Drug Combination Buprenorphine
Depression

Keywords

  • Adherence
  • Buprenorphine/Naloxone
  • Depression
  • Neuropsychological change
  • Opioid agonist treatment
  • Opioid use disorder

ASJC Scopus subject areas

  • Health Policy
  • Psychiatry and Mental health

Cite this

Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone : A preliminary study. / Scott, Travis M.; Rivera Mindt, Monica; Cunningham, Chinazo O.; Arias, Franchesca; Coulehan, Kelly; Mangalonzo, Aprille; Olsen, Pat; Arnsten, Julia H.

In: Substance Abuse: Treatment, Prevention, and Policy, Vol. 12, No. 1, 48, 15.11.2017.

Research output: Contribution to journalArticle

@article{56adeaa681e544aa8a78593a9b8409c2,
title = "Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: A preliminary study",
abstract = "Background: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. Methods: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age=45.2years [SD=8.1]; 25{\%} female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence. Results: Depressive symptomatology was not significantly related to neuropsychological change (p's>.05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r's=.52-60; p's<.05). Conclusions: Among OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD. Trial registration:NCT01108679. Registered 21 April 2010.",
keywords = "Adherence, Buprenorphine/Naloxone, Depression, Neuropsychological change, Opioid agonist treatment, Opioid use disorder",
author = "Scott, {Travis M.} and {Rivera Mindt}, Monica and Cunningham, {Chinazo O.} and Franchesca Arias and Kelly Coulehan and Aprille Mangalonzo and Pat Olsen and Arnsten, {Julia H.}",
year = "2017",
month = "11",
day = "15",
doi = "10.1186/s13011-017-0133-2",
language = "English (US)",
volume = "12",
journal = "Substance Abuse: Treatment, Prevention, and Policy",
issn = "1747-597X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone

T2 - A preliminary study

AU - Scott, Travis M.

AU - Rivera Mindt, Monica

AU - Cunningham, Chinazo O.

AU - Arias, Franchesca

AU - Coulehan, Kelly

AU - Mangalonzo, Aprille

AU - Olsen, Pat

AU - Arnsten, Julia H.

PY - 2017/11/15

Y1 - 2017/11/15

N2 - Background: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. Methods: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age=45.2years [SD=8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence. Results: Depressive symptomatology was not significantly related to neuropsychological change (p's>.05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r's=.52-60; p's<.05). Conclusions: Among OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD. Trial registration:NCT01108679. Registered 21 April 2010.

AB - Background: Among persons with opioid use disorder (OUD), neuropsychological dysfunction is associated with depression, and better neuropsychological function is associated with opioid abstinence. However, it is unknown whether depressive symptomatology or adherence to opiate agonist treatment are associated with neuropsychological change over time. Methods: We recruited 20 buprenorphine/naloxone-treated adults with OUD (M Age=45.2years [SD=8.1]; 25% female) to complete baseline and 6 month visits containing a neuropsychological test battery and self-reported measures of depressive symptomatology and medication adherence. Results: Depressive symptomatology was not significantly related to neuropsychological change (p's>.05). Greater adherence to buprenorphine/naloxone was associated with improvements in learning, memory, and global functioning (r's=.52-60; p's<.05). Conclusions: Among OUD patients, greater adherence to buprenorphine/naloxone is associated with improved neuropsychological functioning over time. In contrast, depressive symptomatology is not associated with neuropsychological functioning over time. Supporting adherence to buprenorphine/naloxone may improve and/or preserve learning and memory functioning in individuals treated for OUD. Trial registration:NCT01108679. Registered 21 April 2010.

KW - Adherence

KW - Buprenorphine/Naloxone

KW - Depression

KW - Neuropsychological change

KW - Opioid agonist treatment

KW - Opioid use disorder

UR - http://www.scopus.com/inward/record.url?scp=85034619151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034619151&partnerID=8YFLogxK

U2 - 10.1186/s13011-017-0133-2

DO - 10.1186/s13011-017-0133-2

M3 - Article

VL - 12

JO - Substance Abuse: Treatment, Prevention, and Policy

JF - Substance Abuse: Treatment, Prevention, and Policy

SN - 1747-597X

IS - 1

M1 - 48

ER -